Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
  • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
  • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
  • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0085—Brain, e.g. brain implants; Spinal cord
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P23/00—Anaesthetics
  • A61P23/02—Local anaesthetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Definitions

• the present invention relates to an acetaminophen injectable solution for spinal administration.
• the present invention originates from the field of drugs in liquid form suitable for spinal administration.
• the present invention relates to an injectable pharmaceutical formulation containing acetaminophen as active ingredient for the treatment of postsurgical pain by spinal administration.
• Acetaminophen acetyl-p-aminophenol
• paracetamol CAS no: 103-90-2
• Acetaminophen is an active ingredient possessing analgesic and antipyretic activity used widely in medical practice to alleviate acute and chronic pain and to reduce the body temperature when this exceeds physiological values.
• Paracetamol conversely to the majority of commonly used analgesic drugs, is not an NSAID (non-steroidal anti-inflammatory drug), since it is almost devoid of antiaggregant and anti-inflammatory activity. To date, its mechanism of action remains little known, although this molecule was synthesised for the first time in 1878 and its use in the medical field has been established for more than 100 years.
• NSAID non-steroidal anti-inflammatory drug
• acetaminophen is used fundamentally as an analgesic in the treatment of mild and medium pain and as an antipyretic in the treatment of febrile states in adults and in children.
• the most common pharmaceutical form for this active ingredient is the solid form.
• the most typical paracetamol-based pharmaceutical formulations are those in solid tablet form, in granule form or in the form of suppositories.
• formulations containing acetaminophen in the form of a solution for intravenous infusion can also be found on the market. These are formulations indicated for the short-term treatment of pain of medium intensity, in particular of the type experienced following a surgical intervention.
• Intravenous administration is reserved for cases in which, from a clinical viewpoint, there is the need to treat the pain and/or hyperthermia with urgency or in cases in which it is impossible to implement the other administration methods.
• acetaminophen is devoid of anaesthetic action, it is yet to be used in the field of general, local or locoregional anaesthesia, such as spinal anaesthesia.
• Spinal anaesthesia is an anaesthesia technique in which an injectable solution containing an active ingredient possessing local anaesthetic activity is injected through the dura mater, that is to say the outer meningeal membrane protecting the spinal cord, into the medullary canal thereof.
• the spinal injection is usually carried out by highly qualified medical personnel between the spinous processes of two vertebrae, usually in the lumbar zone, using specific needles, which are long and slender.
• the solution containing the active ingredient possessing local anaesthetic activity once injected in situ, mixes with the cerebrospinal fluid, that is to say the biological fluid that bathes the spinal cord and is located between the spinal cord and the dura.
• the cerebrospinal fluid that is to say the biological fluid that bathes the spinal cord and is located between the spinal cord and the dura.
• the solution containing the local anaesthetic mixes with the cerebrospinal fluid, thus blocking conduction via the nervous system of impulses to the brain and causing a reversible loss of sensitivity, which may be accompanied by motor paralysis.
• the anaesthesia is thus implemented both from the anterior part of the spinal cord, from which the motor nerves originate, and from the posterior part, from which the sensory nerves enter.
• the administration of the solution containing the anaesthetic then causes the absence of sensitivity of the innervated areas from the nerve roots in question, and at the same time the inhibition of muscular and sensory activity.
• spinal anaesthesia is used for interventions on organs of the small pelvis and on the lower limbs. Typical examples where spinal anaesthesia is used are appendectomy, hernioplasty, caesarean section, arthroscopy, orthopaedic surgery of the lower limbs, etc.
• the intrathecal technique is more invasive than the epidural technique since the injection is performed in a deeper zone of the spine, it has the advantage of requiring comparably lower doses of local anaesthetic.
• This aspect generally constitutes an advantage since local anaesthetics have a certain neurotoxicity.
• the spinal anaesthesia can last from one to three hours approximately. Once this action ceases, the patient progressively regains mobility and sensitivity; the perception of pain increases as time passes due to the effects of the surgical procedure.
• the analgesic action of local anaesthetics therefore fundamentally remains limited to the period of the surgical intervention, for which reason it is essential to establish suitable analgesic therapy in the immediate post-surgical period.
• the sensation of generalised pain is localised in the region of the wound and is in fact particularly intense, and it is therefore necessary to establish an effective and prompt analgesic therapy.
• One of the objects of the present invention is therefore to provide pharmaceutical formulations for spinal administration that make it possible to obtain an effective analgesic action in cases of acute post-surgical pain.
• Another object of the present invention is to provide an injectable solution containing an analgesic active ingredient suitable for spinal administration in the event of locoregional anaesthesia, said solution having an effective and durable analgesic action on the patient when the action of the local anaesthetic runs out.
• the inventors of the present patent application have now found that by administering a supersaturated aqueous solution of acetaminophen by spinal route, a prolonging of the analgesic effect substantially devoid of side effects, is surprisingly obtained.
• the present invention provides an acetaminophen supersaturated injectable aqueous solution for analgesic use by spinal administration, wherein said supersaturated injectable aqueous solution comprises acetaminophen in a concentration ranging from 1.3 to 8% w/v.
• acetaminophen supersaturated aqueous solutions according to the invention with a concentration from 1.3 to 8% w/v are unexpectedly stable, even after a period of storage of more than 18 months.
• the inventors have discovered that, by means of spinal administration of an acetaminophen supersaturated injectable aqueous solution, it is possible to obtain an effective analgesic effect of unexpectedly prolonged duration, typically equal to or greater than 24 hours.
• the spinal administration of an acetaminophen supersaturated solution according to the invention results in effective analgesia for at least 24 hours in mice and in rats in the case of inflammatory pain induced by carrageenan and in post-surgical pain.
• acetaminophen supersaturated aqueous solutions are compatible with conventional solutions of local anaesthetics and can therefore be co-administered by spinal administration. Co-administration with local anaesthetics is made possible or is facilitated in any case since the solutions according to the invention have a quantity of solvent less than that of unsaturated acetaminophen solutions.
• a first limitation is of the physical type, since, in the case of spinal anaesthesia, the drug is perfused in a defined and confined space in which a limited quantity of solution can be infused.
• this limitation is overcome since a therapeutically effective quantity of active ingredient is dissolved in a volume of solvent that is reduced compared to an unsaturated conventional solution of the same active ingredient.
• the low volume of supersaturated solution needed to obtain an analgesic therapeutic response allows the simultaneous administration with local anaesthetic solutions.
• an acetaminophen supersaturated solution with a volume of approximately 0.5-1.5 ml of water can be added to a solution of equal volume of local anaesthetic in order to obtain a total solution of approximately 1-6 ml that can be administered by means of spinal administration without exceeding the physiological limits imposed by the subdural space (intrathecal).
• the acetaminophen supersaturated solution can therefore be added to and/or mixed with a conventional solution of a local anaesthetic in order to obtain effective analgesia for a period of time greater than the period of activity of the anaesthetic, in particular in the case in which the anaesthetic is a short-acting or medium-acting anaesthetic.
• acetaminophen solutions and the local anaesthetic solutions have increased chemical-physical compatibility, which allows these solutions to be used concomitantly or in mixture.
• an acetaminophen supersaturated aqueous solution for analgesic use, comprising its simultaneous, separate or sequential spinal administration with a local anaesthetic.
• spinal administration of the acetaminophen supersaturated solution is implemented before pain is perceived, typically before a surgical intervention.
• the analgesic action determined by the acetaminophen has a positive additive effect, and not a synergistic effect, with respect to the anaesthesia produced by the local anaesthetic.
• the duration of the sensory and motor block remains unchanged.
• the pharmacokinetics of the anaesthetic thus remains unchanged, enabling rapid discharge of the patient in the case of joint administration with short-acting anaesthetics in clinical practice.
• a process for preparing an acetaminophen supersaturated aqueous solution in particular of the type described above, is provided.
• the presence of oxygen or of dissolved air in the solvent is typically eliminated or substantially reduced, thus causing an increase of the stability of the acetaminophen solution.
• a process for preparing an acetaminophen supersaturated solution comprising the dissolution of acetaminophen in a deoxygenated-water-based solvent, for example by degassing with a flow of inert gas, typically nitrogen and/or an inert gas, for example argon.
• inert gas typically nitrogen and/or an inert gas, for example argon.
• the acetaminophen supersaturated solution obtained with the process according to the invention is highly stable, has an increased concentration of acetaminophen in the solvent, and can be mixed with a solution of a conventional local anaesthetic in order to obtain a solution with a total volume that is compatible with the volume injectable by means of spinal administration in a single administration process.
• a method for treating pain, in particular acute post-surgical pain comprising spinal infusion of an acetaminophen supersaturated injectable aqueous solution having a concentration from 1.3 to 8% w/v in a therapeutically effective amount is provided.
• Spinal administration of acetaminophen supersaturated solution can be implemented simultaneously, separately or sequentially with the administration of a local anaesthetic.
• the analgesic treatment method according to the invention comprises the administration of a therapeutically effective quantity of acetaminophen supersaturated solution before pain is perceived, typically before the surgical intervention.
• the analgesic effect achieved has an unexpectedly prolonged duration, for example greater than 24 hours.
• FIG. 1 shows a graph illustrating the analgesic effect over time of two solutions containing, respectively, 10 and 100 pg of acetaminophen in hyperalgesia caused by induction of peripheral inflammation
• FIG. 2 shows a graph illustrating the development of oedema resulting from peripheral inflammation measured as an increase in the volume of the paw of laboratory mice
• FIG. 3 shows a graph illustrating the analgesic effect over time of a solution containing 200 pg of acetaminophen in a model of post-surgical pain in rats
• FIG. 4 shows the effect of co-administration of acetaminophen (200 pg) and a solution of 3 % chloroprocaine (20 pL)
• the invention relates to an acetaminophen injectable aqueous solution for analgesic use by spinal administration, wherein said injectable solution is supersaturated and conveniently comprises acetaminophen dissolved in water in a concentration ranging from .3 to 8% w/v.
• the acetaminophen injectable aqueous solution is supersaturated and has a concentration ranging from 1.8 to 8.0 w/v of acetaminophen.
• the acetaminophen injectable aqueous solution is supersaturated and has a concentration ranging from .3 to 2.3 % w/v.
• concentration ranging from .3 to 2.3 % w/v.
• the acetaminophen supersaturated solution has a concentration of 1.3 to 8% w/v, from 1.8 to 8% w/v, from 1.8 to 3% w/v, from 1.3 to 2.3 % w/v.
• the acetaminophen supersaturated solutions of the invention have a concentration of or greater than 1.8 % w/v.
• the acetaminophen solution is implemented so as to administer a therapeutically active quantity of active ingredient.
• terapéuticaally active means a dose that causes a significant analgesic response in the subject to whom the acetaminophen supersaturated solution is administered. This dose varies according to the conditions, age and weight of the patient.
• the analgesic effect caused by acetaminophen has a positive additive action, and not a synergistic action, with respect to the anaesthesia produced by the local anaesthetic.
• the duration of the sensory and motor block remains unchanged.
• the pharmacokinetics of the anaesthetic thus remains unchanged, enabling a rapid discharge of the patient in the case of joint administration with short-acting anaesthetics in human clinical practice.
• saturated solution means a solution that has dissolved therein the maximum quantity of solute possible at a specific temperature, typically set at 20 °C.
• supersaturated solution means a solution that has a concentration of solute greater than the one that could be dissolved in water, in particular distilled water for pharmaceutical use, at a temperature of 20 °C.
• acetaminophen represents the solute in excess that does not separate spontaneously by crystallisation.
• acetaminophen supersaturated solution means solutions with a concentration of acetaminophen equal to or greater than approximately 13 mg/ml or 1.3 % w/v in water, at a temperature of 20 °C.
• acetaminophen dose means a quantity of acetaminophen and/or salts or derivatives thereof that can effectively cause central locoregional anaesthesia following perfusion via spinal administration.
• the acetaminophen supersaturated solution may have a concentration of acetaminophen no greater than 00 mg/ml, corresponding to 10% w/v, beyond which recrystallisation of the active ingredient may occur.
• the acetaminophen supersaturated solutions according to the invention have an acetaminophen concentration ranging from 1.3 to 2.3 %.
• the solvent phase is water-based, typically sterile and apyrogenic.
• the acetaminophen supersaturated solution is substantially free of preservatives, and/or additives and/or co-solvents.
• the supersaturated solution according to the invention has a pH ranging from 4.5 to 6.5. In some embodiments, this pH range is regulated by adding a buffering agent in suitable quantities.
• the acetaminophen solution according to the invention has a pH substantially equal to 5.5.
• the acetaminophen supersaturated solution according to the invention comprises one or more buffering agents.
• buffering agent used in the formulation of solutions injectable by spinal administration.
• suitable buffering agents comprise carboxylic acids, such as citric acid, or alkaline or earth alkaline phosphates or biphosphates, such as sodium dihydrogen phosphate (Na 2 HP0 4 ).
• the acetaminophen solution according to the invention has an osmolality ranging between 80 and 310 mOsm/kg.
• isoosmotic agents In order to modify the osmolality of the solution itself, it is possible to use isoosmotic agents.
• the acetaminophen solution according to the invention has a relative density at 20 °C ranging between 1.003 and 1.075 g/g.
• the acetaminophen supersaturated aqueous solution according to the invention is used in the treatment and/or in the prevention of pain and in particular in post-surgical analgesic treatment.
• the acetaminophen supersaturated solution is used in the post-surgical analgesic therapy of surgical interventions such as appendectomy, hernioplasty, caesarean section, arthroscopy, orthopaedic surgery of the lower limbs, etc.
• a quantity of acetaminophen ranging from 6 to 60 mg, typically from 8 to 40 mg, is injected by spinal administration.
• the effective dose of acetaminophen administered by spinal administration in the form of a supersaturated solution according to the invention is approximately 1/100 of the dose of acetaminophen administered orally necessary to obtain the same analgesic response.
• the maximum oral dose permitted within 24 hours is equal to 4 g.
• the maximum spinal dose envisaged for human clinical practice is equal to 40 mg, this being a dose that can also be used in patients with hepatic pathologies.
• This drastic reduction of the dosage of active ingredient necessary to obtain an analgesic response comprises a series of advantages in terms of reduction of systemic toxicity of the drug and of side effects.
• the low dosages of acetaminophen necessary to obtain an analgesic effect by spinal administration of the formulation according to the invention considerably reduce the risks of hepatotoxicity associated with the administration of acetaminophen.
• the low volume of acetaminophen supersaturated solution needed to obtain a suitable therapeutic response allows said solution to be mixed or administered simultaneously with other active ingredients in the form of a solution that can be injected by spinal administration, since the post-injection increase in volume of the cerebrospinal fluid returns to within physiological limits.
• the acetaminophen supersaturated solution is administered intrathecally.
• the acetaminophen supersaturated solution according to the invention has a content of air or oxygen dissolved in the water solvent of less than 200 ppb.
• the considerable absence of oxygen increases the stability of the acetaminophen solution according to the invention, making it possible to store it for long periods of time, up to more than 18 months.
• the stability has also been confirmed at low and high temperatures by carrying out studies at 4 °C, 40 °C and 60 °C, and the solutions demonstrated themselves to be stable for at least 3, 6 and 3 months respectively.
• the acetaminophen supersaturated solution contains deoxygenated water as solvent.
• a process for producing an acetaminophen supersaturated solution comprising the solubilisation of acetaminophen in an amount greater than or equal to 13 mg/ml (1.3 % w/v) in deoxygenated water by means of nitrogen flushing is provided.
• the process for preparing the solution according to the invention comprises the mixing of water by injection and acetaminophen in a nitrogen atmosphere or in the presence of a nitrogen stream, in which the acetaminophen is provided in an amount so as to give an acetaminophen supersaturated medicated solution.
• the process for preparing an acetaminophen solution of the invention comprises an elimination step of the oxygen or a degassing step of the solvent, which typically is water.
• the elimination of oxygen or the degassing of the water comprises a step of treatment of water with an inert gas, typically nitrogen and/or a noble gas, for example argon.
• an inert gas typically nitrogen and/or a noble gas, for example argon.
• the process for producing the acetaminophen supersaturated solution comprises the following steps:
• step a) is carried out at a higher temperature than room temperature, for example ranging from 55 to 70°C to produce the supersaturated solution of acetaminophen.
• one or more buffering agents typically citric acid and/or sodium dihydrogen phosphate, are added in order to regulate the pH of said aqueous solution, for example in the range from 4.5 to 6.5.
• step b) of filtration of the acetaminophen solution is carried out by means of sterilising filter.
• Step b) can be carried out at a higher temperature than the ambient temperature, for example ranging from 70 to 80°C.
• step c) of distribution is performed at a temperature greater than room temperature, for example ranging from 55 to 75°C.
• the step d) of sterilisation of the acetaminophen solution is carried out by means of heating, typically to temperatures greater than 100 °C for a period of time suitable for sterilisation, for example equal to or greater than 15 minutes
• the acetaminophen supersaturated solution of the invention is obtained with a process that comprises the following steps:
• the acetaminophen supersaturated solution is packaged in suitable sterile vials in the presence of inert gas, typically nitrogen, in order to prevent oxidative phenomena, which could compromise the stability of the solution.
• inert gas typically nitrogen
• an acetaminophen supersaturated aqueous solution for analgesic use comprising simultaneous, separate or sequential spinal administration with a local anaesthetic is provided.
• the present invention provides an analgesic treatment method comprising the spinal administration of an acetaminophen supersaturated solution according to any one of the previously described embodiments.
• the activation of a neuronal firing is provoked in the affected area, where the paracetamol is effective in controlling the intensity of the ascending stimulus, decreasing the awareness and sensitivity of the algesic threshold thus determining an unexpectedly prolonged analgesic effect.
• the acetaminophen supersaturated solution is administered simultaneously with the administration of a local anaesthetic.
• the simultaneous administration requires the mixing of the acetaminophen solution with a solution of a local anaesthetic.
• acetaminophen supersaturated solution is provided by the possibility of having an elevated content of active ingredient in a reduced volume of solvent.
• the acetaminophen solutions according to the invention typically contain from 1.3 to 2.3 mg per ml of solvent, typically water for injection.
• solutions can be mixed with the solutions of conventional local anaesthetics, which typically have a volume ranging between 1 and 2.5 ml, to obtain a final mixture for infusion with a total volume conveniently ranging from 2 to 4 ml.
• the simultaneous spinal administration of local anaesthetic and acetaminophen supersaturated solution makes it possible to obtain a combined anaesthetic and analgesic effect by carrying out a single spinal injection, thus limiting the risks of injury to the spinal cord of the patient and increasing the compliance with the combined anaesthetic-analgesic treatment.
• the present invention provides a method of combined anaesthetic-analgesic treatment, which comprises the simultaneous, separate or sequential administration of an acetaminophen supersaturated solution and a solution of local anaesthetic.
• a further advantage of the acetaminophen solution according to the invention lies in its compatibility with conventional local anaesthetics.
• anaesthetic that can be administered by spinal administration, independently of its period of action.
• short-acting local anaesthetics such as lidocaine, articaine, oxybuprocaine, chloroprocaine, or a medium-acting local anaesthetic selected from prilocaine, mepivacaine, etidocaine, or a long-acting local anaesthetic selected from ropivacaine, bupivacaine, cinchocaine, levobupivacaine, proxymetacaine and tetracaine are used within the scope of the invention.
• Acetaminophen supersaturated solution injectable by spinal administration having the following formulation:
• the solution had a pH of 5.7
• Acetaminophen supersaturated buffered solution injectable by spinal administration having the following formulation:
• the pH of the solution was approximately 5.5
• Buffered acetaminophen supersaturated solution injectable by spinal administration having the following formulation:
• the pH of the solution was approximately 5.5
• Combined anaesthetic-analgesic formulation injectable by spinal administration having the following formulation:
• acetaminophen solutions were prepared using water deoxygenated by means of nitrogen flushing (oxygen residue ⁇ 200 ppb); in the case of the solutions of acetaminophen alone, initial pH values around 6.0 were obtained independently of the concentration of the acetaminophen itself, in any case ranging between 4.5 and 6.5.
• the active ingredient was solubilised in heated water in defined conditions (approximately 50 °C).
• the solution thus obtained can be stored in the long term within a wide range of temperatures without reprecipitation and/or chemical alteration of the acetaminophen.
• the solubility of the acetaminophen at 20 °C was approximately 13 mg/ml (1 .3 % w/v).
• the water for injection was degassed by means of boiling and was then cooled to 60 °C.
• Acetaminophen and, for the buffered solutions, citric acid and disodium phosphate was/were added.
• the solution was left under stirring, maintaining a constant influx of nitrogen, for 25 minutes.
• the solution was then filtered under nitrogen pressure and was collected in flasks previously purged with inert gas (N2). The solution was distributed into vials in nitrogen stream, and the vials were subjected to final sterilisation in autoclave in overkill conditions (121 °C for 15 minutes).
• the pH of the unbuffered solutions demonstrates a rising trend, starting from values from approximately 6.0 and reaching 6.5 under the condition of maximum stress (60
• the acetaminophen titre remains unchanged.
• the concentration of the dimer always remains less than 0.10 %. No other impurities are observed.
• the acetaminophen solutions were prepared using water deoxygenated by nitration (residual oxygen ⁇ 200 ppb). Initial pH values of around 5.5 were obtained, regardless of the concentration of the acetaminophen itself, in each case of between 4.5 and 6.5. The solubilization of the active ingredient took place in water for injection maintained at a temperature of between 55 and 70°C. The solution thus obtained can be stored at length under these temperature conditions without precipitation and/or chemical alteration of the acetaminophen.
• the water for injections was degassed by boiling and then cooled to 70 °C. Acetaminophen was added. The solution was left under stirring, while maintaining a constant influx of nitrogen and the temperature above 55 °C for 25 minutes.
• the pH of the solutions show an increasing trend starting from values of about 5.5 and reaching 6.0 in the condition of maximum stress (40 °C).
• the titre of the acetaminophen remains unchanged. They 4-aminophenol impurity always remains below the detection limit of the HPLC method used for the analysis. The concentration of the dimer is always less than 0.1 %. No other impurities were detected.
• the solutions with a concentration of acetaminophen of 1.5 % and 2 % w/v of example 5 were mixed with various anaesthetics for spinal use (from the classes of amides and esters, for example bupivacaine HCI, lidocaine HCI, prilocaine HCI, chloroprocaine HCI, mepivacaine HCI, ropivacaine HCI) in various proportions so as to cover the entire known dosage range of each of these anaesthetics and a dosage range of acetaminophen from 10 mg to 60 mg.
• various anaesthetics for spinal use from the classes of amides and esters, for example bupivacaine HCI, lidocaine HCI, prilocaine HCI, chloroprocaine HCI, mepivacaine HCI, ropivacaine HCI
• chloroprocaine 1 % minimum dosage: 4 ml; maximum dosage 5 ml
• chloroprocaine 3 % minimum dosage: 1.3 ml; maximum dosage 1.7 ml hyperbaric prilocaine 2 %: minimum dosage: 2 ml; maximum dosage 3 ml prilocaine 2 %: minimum dosage: 2.5 ml; maximum dosage 4 ml
• ropivacaine 5 mg/ml minimum dosage: 3 ml; maximum dosage 5 ml ropivacaine 10 mg/ml: minimum dosage: 1 .5 ml; maximum dosage 2.5 ml hyperbaric bupivacaine 0.5 %: minimum dosage: 1.5 ml; maximum dosage 4 ml
• mepivacaine 2 % minimum dosage: 1 ml; maximum dosage 3 ml
• mepivacaine 4 % minimum dosage: 0.5 ml; maximum dosage 1.5 ml lidocaine 0.5 %: minimum dosage: 8 ml; maximum dosage 16 ml
• lidocaine 2 % minimum dosage: 2 ml; maximum dosage 4 ml
• the two products were mixed in accordance with the operative procedures commonly used in the field of anaesthesia.
• the solutions were drawn using the same sterile syringe through a needle of 18G diameter and by dispensing the mixture thus created into a glass vial using a needle for spinal anaesthesia (the diameters used were 24G, 25G, and 27G).
• the mixture with minimum dosage of hyperbaric bupivacaine 0.5 % (1.5 ml) and maximum dosage of acetaminophen 2 % (3 ml) was prepared 3 times.
• the first time in accordance with the usual operative procedures, the second time leaving the mixture in the syringe and placing it at a temperature of 4 °C for 10 days, and the third time preparing the mixture at a temperature of 15 °C. In none of these cases was the presence of crystals and/or precipitate observed.
• the pain threshold following mechanical stimulation was measured after 2, 4, 6 and 24 hours after induction of the inflammation. This threshold is to be considered an indicator of inflammatory pain.
• the development of oedema at the site of inflammation was measured and expressed as an increase of volume (ml_) of the site of inflammation.
• N 5 mice received spinal vehicle (IT; to be understood as a placebo) and intraplantar administration of carrageenan
• IT acetaminophen in the dose of 100 pg per mouse was effective in reducing inflammatory pain in the mouse.
• the mice to which IT acetaminophen was administered in the dose of 100 pg had a significantly higher pain threshold following mechanical stimulation of the site of inflammation (figure 1 ).
• IT acetaminophen in the dose of 100 pg per mouse produced only a slight reduction (approximately 20 %) of the development of oedema at the site of inflammation during the first two hours following induction (figure 2).
• IT acetaminophen did not produce any clear sign of toxicity or clear behavioural and motor changes.
• the accompanying figure 1 shows the pain threshold following mechanical stimulation at the site of inflammation after IT administration of placebo, 10 pg of acetaminophen and 100 pg of acetaminophen.
• Figure 2 shows the development of oedema at the site of inflammation during the first two hours after induction after IT administration of placebo, 10 pg of acetaminophen and 100 pg of acetaminophen.
• the raw data and the relative statistical analysis of example 6 will be presented hereinafter.
• Threshold of mechanical hyperalgesia (values expressed in grams)
• Paw volume (oedema) (values expressed in mL)
• the pain threshold following mechanical stimulation (expressed in grams) was measured after 2, 4, 6 and 24 hours after the incision. This threshold is considered to be an indicator of pain and hyperalgesia of the zone affected by surgical intervention.
• N 5 rats received spinal vehicle (IT; to be understood as placebo) immediately before the surgical procedure.
• N 5 rats received acetaminophen IT (200 pg) immediately before the surgical procedure.
• IT acetaminophen in the dose of 200 pg per rat was effective in reducing postsurgical pain, as shown in figure 3.
• the rats to which IT acetaminophen was administered in the dose of 200 pg had a significantly higher pain threshold following mechanical stimulation of the site of incision (figure 3).
• IT acetaminophen in the dose of 200 pg produced significant cumulative analgesia over 24 hours.
• the post-surgical pain was induced by means of incision and subsequent suture of the subplantar region of the rear left paw, as described by Timothy J. Brennan (1996).
• the pain threshold following mechanical stimulation (expressed in grams) was measured 4 hours after the incision. Complete reduction of the anaesthetic effect of the spinal chloroprocaine is expected within this period of time. The reduction of the pain threshold is considered to be an indicator of pain and hyperalgesia of the zone affected by surgical intervention.
• N 5 rats received spinal vehicle (IT; to be understood as placebo) immediately before the surgical procedure
• N 5 rats received acetaminophen IT (200 pg) immediately before the surgical procedure
• N 4 rats received chloroprocaine IT (3 %, 20 pL) immediately before the surgical procedure
• N 4 rats received acetaminophen IT (200 pg) + chloroprocaine IT (3 %, 20 pL) immediately before the surgical procedure.
• IT acetaminophen in the dose of 200 pg per rat was effective in reducing postsurgical pain, as shown in figure 4.
• the rats to which IT acetaminophen was administered in the dose of 200 pg had a significantly higher pain threshold following mechanical stimulation of the site of incision (figure 4).
• IT acetaminophen in the dose of 200 pg for rats in co-administration with chloroprocaine (3 %, 20 ⁇ _) produced a significant rise of the pain threshold following mechanical stimulation of the site of incision with a trend suggestive of an additional analgesic effect.

Landscapes

• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Pain & Pain Management (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Biomedical Technology (AREA)
• Emergency Medicine (AREA)
• Psychology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Anesthesiology (AREA)
• Rheumatology (AREA)
• Dermatology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (32)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=46690603

Family Applications (1)

Country Status (44)

Citations (2)

Family Cites Families (15)

• 2012
  • 2012-06-29 IT IT001154A patent/ITMI20121154A1/it unknown
• 2013
  • 2013-06-27 KR KR1020147036909A patent/KR102118227B1/ko not_active Expired - Fee Related
  • 2013-06-27 WO PCT/IB2013/055277 patent/WO2014002042A1/en not_active Ceased
  • 2013-06-27 MA MA37811A patent/MA37811B1/fr unknown
  • 2013-06-27 EA EA201500065A patent/EA028909B1/ru unknown
  • 2013-06-27 AP AP2014008152A patent/AP2014008152A0/xx unknown
  • 2013-06-27 JP JP2015519450A patent/JP5876620B2/ja not_active Expired - Fee Related
  • 2013-06-27 MY MYPI2014703994A patent/MY169251A/en unknown
  • 2013-06-27 MX MX2014015402A patent/MX369264B/es active IP Right Grant
  • 2013-06-27 GE GEAP201313679A patent/GEP201706689B/en unknown
  • 2013-06-27 NZ NZ703829A patent/NZ703829A/en not_active IP Right Cessation
  • 2013-06-27 MD MDA20140138A patent/MD4537C1/ro not_active IP Right Cessation
  • 2013-06-27 PE PE2014002536A patent/PE20150331A1/es active IP Right Grant
  • 2013-06-27 HR HRP20160706TT patent/HRP20160706T1/hr unknown
  • 2013-06-27 ES ES13765450.5T patent/ES2578012T3/es active Active
  • 2013-06-27 UA UAA201413899A patent/UA117101C2/uk unknown
  • 2013-06-27 SG SG11201408479WA patent/SG11201408479WA/en unknown
  • 2013-06-27 PL PL13765450.5T patent/PL2874602T3/pl unknown
  • 2013-06-27 RS RS20160435A patent/RS54844B1/sr unknown
  • 2013-06-27 HU HUE13765450A patent/HUE029431T2/en unknown
  • 2013-06-27 DK DK13765450.5T patent/DK2874602T3/en active
  • 2013-06-27 CN CN201380034500.0A patent/CN104487051B/zh not_active Expired - Fee Related
  • 2013-06-27 PT PT137654505T patent/PT2874602T/pt unknown
  • 2013-06-27 EP EP13765450.5A patent/EP2874602B1/en active Active
  • 2013-06-27 CA CA2876801A patent/CA2876801C/en active Active
  • 2013-06-27 SI SI201330208A patent/SI2874602T1/sl unknown
  • 2013-06-27 ME MEP-2016-118A patent/ME02431B/me unknown
  • 2013-06-27 AU AU2013282753A patent/AU2013282753B2/en not_active Ceased
  • 2013-06-27 US US14/411,532 patent/US11344517B2/en active Active
  • 2013-06-27 SG SG10201704482YA patent/SG10201704482YA/en unknown
  • 2013-06-27 BR BR112014032818-8A patent/BR112014032818B1/pt not_active IP Right Cessation
  • 2013-06-28 AR ARP130102331 patent/AR091633A1/es unknown
• 2014
  • 2014-12-18 TN TN2014000526A patent/TN2014000526A1/fr unknown
  • 2014-12-18 NI NI201400147A patent/NI201400147A/es unknown
  • 2014-12-22 ZA ZA2014/09478A patent/ZA201409478B/en unknown
  • 2014-12-23 IL IL236423A patent/IL236423A/en active IP Right Grant
  • 2014-12-26 CL CL2014003536A patent/CL2014003536A1/es unknown
  • 2014-12-26 CU CUP2014000150A patent/CU20140150A7/es unknown
  • 2014-12-29 DO DO2014000302A patent/DOP2014000302A/es unknown
• 2015
  • 2015-01-08 EC ECIEPI2015500A patent/ECSP15000500A/es unknown
  • 2015-01-27 CR CR20150036A patent/CR20150036A/es unknown
  • 2015-01-27 PH PH12015500178A patent/PH12015500178B1/en unknown
  • 2015-01-27 CO CO15015754A patent/CO7240357A2/es unknown
• 2016
  • 2016-01-19 US US15/001,064 patent/US20160128955A1/en not_active Abandoned
  • 2016-06-28 CY CY20161100584T patent/CY1117691T1/el unknown
  • 2016-07-26 SM SM201600248T patent/SMT201600248B/it unknown

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events